Talus Bio
PrivateLast Round
Seed
Aug 20, 2024
Est. Valuation
$19.7M
Total Funding Raised
$24.26M
Company Overview
Talus Bio operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Seed round in August 2024.
Talus Bio is a biotechnology company that offers a data-enabled drug development platform for small-molecule therapies in oncology, integrating cell processing, high-sensitivity quantitative proteomics, and machine learning analytics to enhance drug discovery through gene regulation.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Talus Bio Comparables
Compare Talus Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QUANTRO Therapeutics | 84% | |
| Altay Therapeutics | 83% | |
| Rezo Therapeutics | 82% |
For institutional investors. Book with your work email.
Talus Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Aug 20, 2024 | ||||
| Grant | Aug 18, 2023 | ||||
| Seed | Jun 6, 2022 | ||||
| Pre Seed | Oct 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Talus Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NFX | Seed |
| NIH RADx | Seed, Grant |
| WRF Capital | Seed |
| Boom Capital | Seed |
| Two Bear Capital | Seed |
| Washington Research Foundation Capital | Seed |
| BoxOne Ventures | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 17, 2026
Grew 15% QoQ, from 26 to 30 employees.
- Apr 25, 2025
Presented preclinical data on transcription factor therapeutic programs at AACR 2025.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 1, 2026
Talus Bioscience, Inc. launches Ptarmigan-1, a structure-free model that unlocks drug discovery for targets outside the reach of traditional structure-based models, in Jul '26.
For institutional investors. Book with your work email.
Talus Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Talus Bio's valuation, stock price, and market status.
Is Talus Bio a public or private company?
Talus Bio is a private company.
What is the current stock price of Talus Bio?
Talus Bio is a private company, so its shares have no public market price. Caplight tracks Talus Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Talus Bio worth (valuation)?
Talus Bio's valuation is estimated at $19.7M based on funding round data.
Can I buy Talus Bio stock?
Talus Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Talus Bio's last funding round?
Talus Bio's most recent funding round was Seed on August 20, 2024.
Who are the main investors in Talus Bio?
Key investors in Talus Bio include NFX, Two Bear Capital, Fifty Years.
Will Talus Bio IPO soon?
No public IPO plans have been announced for Talus Bio.
How can I track Talus Bio secondary market activity?
Caplight tracks bids, offers, and trades in Talus Bio's shares on secondary markets.